Cope, AP, Jasenecova, M, Vasconcelos, JC, Filer, A, Raza, K, Qureshi, S
, D'Agostino, MA, Mcinnes, IB, Isaacs, JD, Pratt, AG, Fisher, BA, Buckley, CD, Emery, P, Ho, P, Buch, MH, Ciurtin, C, Van Schaardenburg, D, Huizinga, T, Toes, R, Georgiou, E, Kelly, J, Murphy, C, Prevost, AT, Norton, S, Lempp, H, Opena, M, Subesinghe, S, Garrood, T, Menon, B, Ng, N, Douglas, K, Koutsianas, C, Cooles, F, Falahee, M, Echavez-Naguicnic, I, Bharadwaj, A, Villaruel, M, Pande, I, Collins, D, Pegler, S, Raizada, S, Siebert, S, Fragoulis, G, Guinto, J, Galloway, J, Rutherford, A, Barnes, T, Jeffrey, H, Patel, Y, Batley, M, O'Reilly, B, Venkatachalam, S, Sheeran, T, Gorman, C, Reynolds, P, Khan, A, Gullick, N, Banerjee, S, Mankia, K, Jordan, D, Rowlands, J, Starmans-Kool, M, Taylor, J, Nandi, P, Sahbudin, I, Maybury, M, Hider, S, Barcroft, A, Mcnally, J, Kitchen, J, Nisar, M & Quick, V 2024, '
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial',
The Lancet, vol. 403, pp. 838-849.
https://doi.org/10.1016/s0140-6736(23)02649-1